Halozyme Therapeutics (HALO) director sells 1,626 shares in Rule 10b5-1 plan trade

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported a sale of 1,626 shares of common stock on 2026-08-10 at $102.80 per share. After this transaction, she directly holds 40,418 shares. The sale was made under a Rule 10b5-1 written trading plan adopted on May 29, 2025.

Insider Trade Summary 10b5-1

Net Seller: 1,626 shares

Net Sell 1 txn

Insider Connaughton Bernadette

Role Director

Sold 1,626 shs ($167K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,626	$102.80	$167K

Holdings After Transaction: Common Stock — 40,418 shares (Direct)

Footnotes (1)

1. F1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

Key Figures

Shares sold: 1,626 shares Sale price per share: $102.80 Shares held after sale: 40,418 shares +1 more

4 metrics

Shares sold 1,626 shares Common stock sale on 2026-08-10 by director Bernadette Connaughton

Sale price per share $102.80 Price per share for the 1,626 common shares sold

Shares held after sale 40,418 shares Total common shares directly owned following the transaction

Rule 10b5-1 plan adoption date May 29, 2025 Date the written trading plan governing these sales was adopted

Key Terms

Rule 10b5-1, written trading plan, sale in open market or private transaction

3 terms

Rule 10b5-1 regulatory

"adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

written trading plan regulatory

"The sales reported ... were made pursuant to a written trading plan"

sale in open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction""

FAQ

What insider transaction did HALO (HALOZYME THERAPEUTICS, INC.) report?

HALO reported that director Bernadette Connaughton sold 1,626 shares of common stock on 2026-08-10 at $102.80 per share, leaving her with 40,418 shares held directly.

Was the August 10, 2026 HALO insider sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were made pursuant to a written trading plan adopted on May 29, 2025 in accordance with Rule 10b5-1, indicating a pre-arranged trading program.

How many HALO shares did Bernadette Connaughton sell and at what price?

Director Bernadette Connaughton sold 1,626 shares of HALO common stock at a price of $102.80 per share. The transaction is reported as a sale in open market or private transaction.

How many HALO shares does the reporting director hold after the reported sale?

Following the reported transaction, Bernadette Connaughton directly holds 40,418 shares of HALO common stock. This figure is listed as the total shares following the transaction in the Form 4 data.

What does the transaction code 'S' mean in the HALO Form 4 filing?

The transaction code "S" in the HALO Form 4 refers to a sale in open market or private transaction. In this case it covers the sale of 1,626 common shares at $102.80 per share by the reporting director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 05:44 PM Accepted by SEC EDGAR 08/11/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connaughton Bernadette

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/10/2026		S(1)		1,626	D	$102.8	40,418	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)